- $67.79m
- $55.28m
- $0.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.01 | ||
| Price to Tang. Book | 10.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 135.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -98.66% | ||
| Return on Equity | -197.92% | ||
| Operating Margin | -2365% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.61 | -0.48 | 28.83 | n/a | 0.5 | n/a | n/a | -17.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
Directors
- Elizabeth Garofalo CHM (64)
- Matthias Schroff PRE (53)
- Elias Papadimas CFO
- Douglas Feltner OTH (61)
- Jeffrey Cleland IND (56)
- Bali Muralidhar IND (41)
- James Sulat IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 6th, 2017
- Public Since
- May 9th, 2018
- No. of Shareholders
- 101
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,317,771
- Address
- 2430 N. HALSTED ST., CHICAGO, 60614
- Web
- https://www.exicuretx.com/
- Phone
- +1 8476731700
- Auditors
- Marcum LLP
Upcoming Events for XCUR
Exicure Inc Annual Shareholders Meeting
Q2 2025 Exicure Inc Earnings Release
Similar to XCUR
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Exicure share price?
As of Today at 20:33 UTC, shares in Exicure are trading at $10.73. This share price information is delayed by 15 minutes.
How has the Exicure share price performed this year?
Shares in Exicure last closed at $10.73 and the price had moved by +328.34% over the past 365 days. In terms of relative price strength the Exicure share price has outperformed the S&P500 Index by +286.25% over the past year.
What are the analyst and broker recommendations for Exicure?
The overall consensus recommendation for Exicure is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Exicure dividend yield?
Exicure does not currently pay a dividend.
Does Exicure pay a dividend?
Exicure does not currently pay a dividend.
When does Exicure next pay dividends?
Exicure does not currently pay a dividend.
How do I buy Exicure shares?
To buy shares in Exicure you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Exicure?
As of the previous close price of $10.73, shares in Exicure had a market capitalisation of $67.79m.
Where are Exicure shares listed?
Here are the trading details for Exicure:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: XCUR
What kind of share is Exicure?
Based on an overall assessment of its quality, value and momentum Exicure is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Exicure share price forecast for 2025?
The analyst consensus target price for shares in Exicure is $2.00. That is 81.36% below the last closing price of $10.73.
Analysts covering Exicure currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Exicure share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exicure. Over the past six months, its share price has outperformed the S&P500 Index by +241.11%.
As of the last closing price of $10.73, shares in Exicure were trading +26.41% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Exicure PE Ratio?
The Exicure PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Exicure?
Exicure's management team is headed by:
- Elizabeth Garofalo - CHM
- Matthias Schroff - PRE
- Elias Papadimas - CFO
- Douglas Feltner - OTH
- Jeffrey Cleland - IND
- Bali Muralidhar - IND
- James Sulat - IND